Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Want to cut your energy bills? Here’s how five experts are doing it 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
PRINCETON, N.J., March 01, 2017 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company announced today that its Chief Executive Officer, Al Altomari will present at 29th Annual ROTH Conference on Monday, March 13, 2017 at 4:30 PM Pacific Time. The conference is being held at the Ritz Carlton Hotel in Dana Point, CA.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of the Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
